Uncategorized
VIDEO: Update on Allegro’s phase 2b clinical trials
LAS VEGAS — At the Ophthalmology Innovation Summit, Vicken Karageozian, MD, chief technical officer of Allegro Ophthalmics, discusses progress of the company's Luminate (ALG-1001) program and gives an update on phase 2b clinical trials and use of the integrin peptide across multiple vitreoretinal indications, including vitreomacular traction, diabetic macular edema and posterior vitreous detachment.